相当于500多万人民币
Adaptimmune is launching Tecelra — a one-time treatment — at a list price of $727,000, the most expensive per-dose cost of any cellular medicine for cancer in the U.S.
https://www.biopharmadive.com/news/adaptimmune-tecelra-fda-approval-synovial-sarcoma-tcr-cell-therapy/723156/
一批准国内就报道了:
https://mp.weixin.qq.com/s/MKieLSCwtzcWk5XoVG_E3g